exRNAdisease

General Information

Database ID:

exR0087742

RNA Name:

hsa-miR-130a-3p

RNA Type:

miRNA

Chromosome:

chr11

Starnd:

Coordinate:

Start Site(bp):

57641252

End Site(bp):

57641273

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ZNF74	chr22	20394115	20408461	+
E2F3	chr6	20401879	20493714	+
CD151	chr11	832887	839831	+
LENG8	chr19	54448887	54462037	+
MTMR9	chr8	11284816	11328146	+
LYSMD2	chr15	51723011	51751585	-
SH3PXD2A	chr10	103594027	103855543	-
STK4	chr20	44966479	45080021	+
STK38L	chr12	27243968	27325959	+
TOMM70	chr3	100363431	100401089	-
G6PD	chrX	154531391	154547572	-
UBQLN1	chr9	83659968	83707958	-
SLC12A7	chr5	1050384	1112063	-
AKAP10	chr17	19904302	19978343	-
STARD13	chr13	33103137	33350630	-
ZBTB7B	chr1	155002630	155018522	+
CALU	chr7	128739292	128773400	+
ZNF12	chr7	6688433	6706947	-
TMF1	chr3	69019827	69052339	-
SNX27	chr1	151612006	151699091	+
PTEN	chr10	87863625	87971930	+
GPRC5A	chr12	12890782	12917937	+
PCYOX1	chr2	70257386	70281185	+
ATP6V1C1	chr8	103021063	103073051	+
TRIM2	chr4	153152342	153339317	+
MSTO1	chr1	155610188	155614971	+
GAS2L1	chr22	29306582	29312785	+
FAM102A	chr9	127940582	127980989	-
LIPA	chr10	89213569	89414557	-
PDRG1	chr20	31944337	31952046	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000591	chr15	41961025	41962156	+
hsa_circ_0001454	chr4	154524454	154533552	+
hsa_circ_0000384	chr12	27867712	27877119	+
hsa_circ_0001723	chr7	91924202	91948826	+
hsa_circ_0000892	chr19	11941431	12014514	+
hsa_circ_0001605	chr6	42903447	42905047	+
hsa_circ_0000155	chr1	168007608	168014465	+
hsa_circ_0001495	chr5	68470703	68471364	+
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0000018	chr1	15860731	15863309	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC011503.2	chr19	23927788	23929287	+
AC021092.1	chr19	44103007	44113183	-
AC135050.6	chr16	31122235	31124064	+
AC234582.1	chr1	155195004	155205495	+
AL031595.3	chr22	44139365	44153626	+
AL049840.4	chr14	103694516	103695050	-
AL158206.1	chr9	19453209	19455173	+
AL158825.2	chr9	75009828	75016036	-
AL603839.3	chr1	40493157	40508661	-
CKMT2-AS1	chr5	81201341	81301565	-
H19	chr11	1995176	2001470	-
HAGLR	chr2	176164051	176188958	-
KCNQ1OT1	chr11	2608328	2699994	-
LINC01089	chr12	121795267	121803906	-
MIR17HG	chr13	91347820	91354579	+
NEAT1	chr11	65422774	65445540	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.